1294-16-2

Basic information

• Product Name: (S_p)-[(1,2,3,3a,8a-η)-1,8-dihydro-8-oxocyclopent[a]inden-1-yl](η5-2,4-cyclopentadien-1-yl)iron(II)
• CAS NO: 1294-16-2
• Molecular Weight: 288.129
• Mol File: 1294-16-2.mol
• Article Data: 2

Chemical Properties

• CAS DataBase Reference: (S_p)-[(1,2,3,3a,8a-η)-1,8-dihydro-8-oxocyclopent[a]inden-1-yl](η5-2,4-cyclopentadien-1-yl)iron(II)(CAS DataBase Reference)
• NIST Chemistry Reference: (S_p)-[(1,2,3,3a,8a-η)-1,8-dihydro-8-oxocyclopent[a]inden-1-yl](η5-2,4-cyclopentadien-1-yl)iron(II)(1294-16-2)
• EPA Substance Registry System: (S_p)-[(1,2,3,3a,8a-η)-1,8-dihydro-8-oxocyclopent[a]inden-1-yl](η5-2,4-cyclopentadien-1-yl)iron(II)(1294-16-2)

Safety Data

• Hazardous Substances Data: 1294-16-2(Hazardous Substances Data)

Upstream product

• 109800-02-4 (o-Iodobenzoyl)ferrocene 
• 89670-19-9 2-bromophenyl ferrocenyl ketone 

Relevant articles and documents

Enantioselective Synthesis of Planar Chiral Ferrocifens that Show Chiral Discrimination in Antiproliferative Activity on Breast Cancer Cells

The design and first enantioselective synthesis of a series of chiral ferrocifens and ferrociphenols was realised by enantioselective palladium-catalysed intramolecular direct C?H bond activation followed by McMurry coupling. Biological evaluation revealed moderate anticancer activities on breast cancer cells and evidence of chiral discrimination between enantiomers. Treatment of the novel ferrocifens with Ag2O revealed that these systems are unable to form a neutral quinone methide, yet still demonstrate marked antiproliferative properties against both the hormone-dependent MCF-7 and hormone-independent MDA-MB-231 cell lines. This bioactivity arises from two mechanisms: Fenton-type chemistry and the anti-estrogenic activity associated with the tamoxifen-like structure.